Compare Conagra Brands Inc (CAG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs Incyte Corporation — how do they compare? Conagra Brands Inc trades at $14.95 (market cap $7.14B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 3.4× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 8.2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| CAG | INCY | |
|---|---|---|
Market Cap | $7.14B | $24.54B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $129.93 |
52-Week Low | $12.58 | $81.61 |
Enterprise Value | $14.20B | $20.04B |
Dividend Yield | 8.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $15.06, up 1.89% with mixed technical signals showing neutral overall momentum. The company faces fundamental challenges with negative net income margin (-16.99%) and ROE (-25.06%) despite recent earnings beats. Recent developments include a 50% dividend cut to $0.18, new executive appointments, and strategic shifts under CEO John Brase to address margin pressure and declining sales.
While CAG's low valuation (P/E 10.06, P/S 0.63) offers potential upside, persistent revenue declines and margin compression present significant headwinds. Analyst consensus remains cautious with 62.5% hold ratings, though the company's debt reduction efforts and operational simplification could support a turnaround if execution improves.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
